Myocardial metabolic background on chemotherapy and means of their correction
- Authors: Vasyuk Y.A1, Shkolnik E.L1, Nesvetov V.V1, Shkolnik L.D2, Varlan G.V2, Pilschikov A.V3
-
Affiliations:
- Moscow State University of Medicine and Dentistry
- 14th Korolenko City Clinical Hospital
- 20th Moscow City Policlinic
- Issue: Vol 4, No 4 (2013)
- Pages: 20-24
- Section: Articles
- URL: https://journals.rcsi.science/2221-7185/article/view/45027
- DOI: https://doi.org/10.26442/CS45027
- ID: 45027
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Yu. A Vasyuk
Moscow State University of Medicine and Dentistryд-р мед. наук, проф., зав. каф. клин. функциональной диагностики
E. L Shkolnik
Moscow State University of Medicine and Dentistry
Email: eshkolnik@mail.ru
д-р мед. наук, проф. каф. клин. функциональной диагностики
V. V Nesvetov
Moscow State University of Medicine and Dentistryассистент каф. клин. функциональной диагностики
L. D Shkolnik
14th Korolenko City Clinical Hospitalд-р мед. наук, проф., зав. онкохирургическим отд-нием
G. V Varlan
14th Korolenko City Clinical Hospitalд-р мед. наук, зав. химиотерапевтическим отд-нием
A. V Pilschikov
20th Moscow City Policlinicврач онколог
References
- Chu E. Physicians' Cancer Chemotherapy Drug Manual 2013. Jones & Bartlett Publishers 2012.
- Swain S, Whaley F.S, Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–79.
- Mercuro G, Cadeddu C, Piras A et al. Early epirubicin - induced myocardial dysfunction revealed by serial tissue doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007; 12: 1124–33.
- Von Hoff D.D, Layard M.W, Basa P et al. Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 1979; 91: 710–7.
- Minotti G, Menna P, Salvatorelli E et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229.
- Tokarska-Schlattner M, Wallimann T, Schlattner U. Alterations in myocardial energy metabolism induced by the anti - cancer drug doxorubicin. C R Biol 2006; 329 (9): 657–68.
- Jeyaseelan R, Poizat C, Wu H.Y, Kedes L. Molecular mechanisms of doxorubicin - induced cardiomyopathy. Selective suppression of Reiske iron - sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 1997; 272: 5828–32.
- Pelikan P.C, Weisfeldt M.L, Jacobus W.E et al. Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. J Cardiovasc Pharmacol 1986; 8: 1058–66.
- Nicolay K, Aue W.P, Seelig J et al. Effects of the anti - cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31PNMR and implications for adriamycin - induced cardiotoxicity. Biochim Biophys Acta 1987; 929: 5–13.
- Eidenschink A.B, Schroter G, Muller-Weihrich S, Stern H. Myocardial high - energy phosphate metabolism is altered after treatment with anthracycline in childhood. Cardiol Young 2000; 10: 610–7.
- Praet M, Ruysschaert J.M. In - vivo and in - vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives. Biochim Biophys Acta 1993; 1149: 79–85.
- Nony P, Guastalla J-P, Rebattu P et al. In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy. Cancer Chemother Pharmacol 2000; 45: 375–80.
- Muraoka S, Miura T. Inactivation of mitochondrial succinatede - hydrogenase by adriamycin activated by horseradish peroxidase and hydrogen peroxide. Chem Biol Interact 2003; 145: 67–75.
- Zhou S, Starkov A, Froberg M.K et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001; 61: 771–7.
- Lopaschuk G.D, Belke D.D, Gamble J et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994; 1213: 263–76.
- Bordoni A, Biagi P, Hrelia S. The impairment of essential fatty acid metabolism as a key factor in doxorubicin - induced damage in cultured rat cardiomyocytes. Biochim Biophys Acta 1999; 1440: 100–6.
- Hong Y.M, Kim H.S, Yoon H.R. Serum lipid and fatty acid profiles in adriamycin - treated rats after administration of L-carnitine. Pediatr Res 2002; 51: 249–55.
- Wakasugi S, Fischman A.J, Babich J.W et al. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 1993; 34: 1529–35.
- Hrelia S, Fiorentini D, Maraldi T et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta 2002; 1567: 150–6.
- Tokarska-Schlattner M, Wallimann T, Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity Mol Pharmacol 2002; 61: 516–23.
- Taegtmeyer H. Metabolism – the lost child of cardiology. J Am Coll Cardiol 2000; 36: 1386–8.
- Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure J Physiol 2003; 555 (1): 1–13.
- Schaper J, Froede R, Hein St et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991; 83: 504–14.
- Sabbah H.N, Sharov V, Riddle J.M et al. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1992; 24: 1333–47.
- De Sousa E, Veksler V, Minajeva A et al. Subcellular creatine kinase alterations – Implications in heart failure. Circ Res 1999; 85: 68–76.
- Lopaschuk G.D, Barr R, Thomas P.D, Dyck J.R. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long - chain 3- ketoacyl coenzyme a thiolase. Circ Res 2003; 93 (3): e33–7.
- Lopaschuk G.D, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 1998; 30: A112–A113.
- Хадзегова А.Б., Васюк Ю.А., Ющук Е.Н. и др. Возможности миокардиальной цитопротекции в комплексном лечении больных с хронической сердечной недостаточностью. Кардиология. 2006; 11: 48–56.
- Gao D, Ning N, Niu X et al. Trimetazidine: a meta - analysis of randomised controlled trials in heart failure. Heart 2011; 97 (4): 278–86.
- Zhang L, Lu Y, Jiang H et al. Additional use of trimetazidine in patients with chronic heart failure: a meta - analysis. J Am Coll Cardiol 2012; 59 (10): 913–22.
- Amal Mohamed Moustafa Y, Amany Abd-Elrahman M. Shalahy impact of trimetazidine on doxorubicin - induced acute cardiotoxicity in mice:a biochemical and electron microscopic study. Egyptian J Histology 2006; 29 (1): 125–36.
- Li Y.J, Wang P.H, Chen C et al. Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacol Sin 2010; 31 (5): 560–9.
- Pascale C, Fornengo P, Epifani G et al. Cardioprotection of trimetazidine and anthracycline - induced acute cardiotoxic effects. Lancet 2002; 359: 1153–4.
- Калинкина Н.В. Влияние триметазидина на безболевую ишемию миокарда и диастолическую функцию левого желудочка у пациентов, получающих антрациклиновые антибиотики. Вестн. неотложной и восстановительной медицины. 2006; 2: 195–8.
- Ватутин Н.Т., Калинкина Н.В., Риджок В.В., Столика О.И. Влияние триметазидина на вариабельность сердечного ритма и систолическую функцию левого желудочка у пациентов, получающих антрациклиновые антибиотики. Кровообіг та гемостаз. 2005; 3–4: 141–5.
- Tallarico D, Rizzo V, Di Maio F. Myocardial cytoprotection by trimetazidine against anthracycline - induced cardiotoxicity in anticancer chemotherapy Angiology 2003; 54 (2): 219–2.
- Carracedo A, Cantley L.C, Pandolfi P.P. Cancer metabolism: fatty acid oxidation in the limelight Nature Reviews Cancer/AOP 2013; doi: 10.1038/nrc3483
![](/img/style/loading.gif)